Orion Group Holdings, Inc. ORN

Iadademstat is under clinical development in acute myeloid leukemia (AML), including in combination with gilteritinib in the Phase Ib FRIDA trial in patients with FLT3-mutated relapsed/refractory (R/R) AML FRIDA data presented at EHA-2026 showed a high composite complete remission (CRc) rate of 67% in heavily pretreated FLT3-mutated R/R AML patients, together with a favorable safety profile MADRID and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733

Despite a GAAP loss, Orion Group Holdings Inc (ORN) reports robust revenue growth and a thriving concrete business, while adjusting guidance to reflect marine segment delays.

ORN stock dips after Q2 earnings miss estimates as Marine project delays cut volumes, margins and guidance despite strong Concrete growth.

Moby summary of Orion Group Holdings, Inc.'s Q2 2026 earnings call

Although the revenue and EPS for Orion Marine (ORN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company” or “Orion”), a leading specialty construction company, today reported its financial results for the second quarter ended June 30, 2026, and updated its full-year 2026 outlook. Highlights for the quarter ended June 30, 2026 Revenue of $221.9 million, GAAP net loss of $4.1 million, or $0.10 per diluted share, Adjusted EBITDA of $7.9 million and Adjusted EPS of $0.02 per diluted shareBooked awards and c

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profileIn FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%Enrollment initiated in Phase II trial of iadademstat in essent

Conference Call to be held Wednesday, July 29, 2026, at 8:00 a.m. Central TimeHOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN), a leading specialty construction company, today announced that it will issue its second quarter 2026 financial results after the close of the stock market on Tuesday, July 28, 2026. A conference call and audio webcast with analysts and investors will be held the next day, Wednesday, July 29, 2026, at 9:00 a.m. Eastern Time/8:00 a.m. Cent